Dublin Woman, 36, Dies In Highway 24 Crash
Dublin Woman, 36, Dies In Highway 24 Crash - Dublin, CA - Authorities said she may have suffered a medical emergency that caused her to lose control of her Tesla.
Source: patch.com
📰 Janice Lu News
Janice Lu News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Janice Lu. Real-time updates on events, politics, business and more.
Orserdu Boosts PFS in ESR1-Mutated Metastatic Breast Cancer Subgroups
Patients with ER-positive, HER2-negative, ESR1-mutant advanced breast cancer experienced improvements in progression-free survival when being treated with Orserdu, study results showed.
United States San Antonio Janice Lu Northwestern University Lurie Comprehensive Cancer Center Antonio Breast Cancer Symposium Breast Cancer
Source: curetoday.com
Elacestrant Improves PFS in ESR1-Mutant Metastatic Breast Cancer Subgroups
Treatment with elacestrant led to a clinically meaningful improvement in progression-free-survival compared with standard-of-care therapy among patients with estrogen receptor–positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
San Antonio United States Janice Lu Northwestern University Lurie Comprehensive Cancer Center Antonio Breast Cancer Bidardf C
Source: onclive.com
Ensuring Access to Oral SERDs
Dr Langer reviews how physicians can ensure that patients get access to oral selective estrogen receptor degraders (SERDs), and the panel of experts provide their closing thoughts.
Source: ajmc.com
Payer Perspectives on SERDs
Dr Langer explores how payers think about the authorization process for DEXA scans and other surveillance activities that would be required for selective estrogen receptor degraders (SERDs) and how oral SERDs affect quality of life.
Lucyr Langer Janice Lu Ryan Haumschild Javier Cortes Enhancing Oncology Model Estrogen Receptors Degraders
Source: ajmc.com
Cardiovascular Risk and Menopausal Symptoms Associated With Oral SERDs
Drs Vidula and Lu review the potential impact of cardiovascular health associated with oral selective estrogen receptor degraders (SERDs) and discuss how the risk of menopausal symptoms differ between oral SERDs and other endocrine therapies.
Neelima Vidula Janice Lu Ryan Haumschild Estrogen Receptors Degraders Er Her2 Metastatic Breast Cancer Bone Health
Source: ajmc.com
Monitoring and Managing Adverse Effects With Oral SERDs
Drs Vidula and Lu discuss how to monitor patients for adverse effects or oral selective estrogen receptor degraders (SERDs) and how those adverse effects are managed.
Source: ajmc.com
Treatment Failure and Resistance Before Oral SERDs
Drs Lu and Vidula discuss treatment failure with other agents that are used before oral selective estrogen receptor degraders (SERDs) and treatment resistance in patients with ER+/HER2- metastatic breast cancer.
Source: ajmc.com
Clinical Impact of Oral SERDs
Dr Lu and Dr Vidula review the clinical impact of oral selective estrogen receptor degraders (SERDs) on disease progression and response rates in patients with ER+/HER2- metastatic breast cancer and discuss if oral SERDs can be used in combination with other therapies in patients.
Ryan Haumschild Neelima Vidula Janice Lu Estrogen Receptors Degraders Er Her2 Metastatic Breast Cancer Clinical Impact
Source: ajmc.com
ESR1 Mutation Confirmation With Oral SERDs
Dr Lu discusses whether ESR1 mutation confirmation is required to consider therapy with oral selective estrogen receptor degraders.
Source: ajmc.com